Playing Catch-Up: Mylan And Biocon To Team Up On Generic Biologics
This article was originally published in The Pink Sheet Daily
U.S. generics giant and Indian biotech hope their collaboration will position them against Teva/Lonza, Sandoz, and other potential competitors.
You may also be interested in...
Expanded technological capabilities, narrowed focus on alternative dosage forms and harder-to-replicate products, and growing international reach are among the strategies being employed by Teva, Mylan and Watson in the face of 2013’s anticipated reverse patent cliff.
In its first investor meeting in four years, Mylan lays out plans to barge over the generics industry’s post-2013 so-called ‘reverse patent cliff’ by focusing on high-barrier-to-entry products – including generic Advair – and portfolio and geographic diversification.
At a Feb. 21 investor day, Mylan discussed its long-term goals for launching several biosimilars, as well some hard-to-reproduce generic offerings.